• Phio Pharmaceuticals filed an FDA meeting request with a briefing package to support PH-762’s next-stage clinical development in cutaneous squamous cell carcinoma.
• Submission follows completion of a Phase 1b trial; Phio outlined a planned Phase 2b neoadjuvant study.
• Clinical supply manufacturing is underway; availability targeted for Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202609140700NEWSFILECNPR____20260914_314020_1) on September 14, 2026, and is solely responsible for the information contained therein.